C07F9/65392

Activators of glucokinase

The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinsae activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.

MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF

This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors.

##STR00001##

Heteroaryl compounds as inhibitors of TYK2, composition and application thereof
20240343747 · 2024-10-17 ·

The present disclosure provides phosphonate-containing heterocycle compounds with TYK2 kinase inhibitory activity, pharmaceutical compositions comprising the same, and applications thereof. The present disclosure provides compounds of Formula (I), as inhibitors of TYK2 kinase. These compounds can be used for preventing and/or treating TYK2 kinase-related diseases and/or conditions.

##STR00001##

Mitotic kinesin inhibitors and methods of use thereof

This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. ##STR00001##

NOVEL ACTIVATORS OF GLUCOKINASE

The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinsae activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.

MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF

This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors.

##STR00001##